Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
13 mai 2024 16h30 HE
|
Sutro Biopharma, Inc.
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - ...
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
30 avr. 2024 08h00 HE
|
Sutro Biopharma, Inc.
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization...
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
02 avr. 2024 06h18 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
25 mars 2024 16h30 HE
|
Sutro Biopharma, Inc.
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling...
Sutro Biopharma to Participate in Upcoming Investor Conferences
06 févr. 2024 16h05 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
04 janv. 2024 16h05 HE
|
Sutro Biopharma, Inc.
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients,...
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
14 déc. 2023 16h05 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
11 déc. 2023 16h05 HE
|
Sutro Biopharma, Inc.
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in...
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
04 déc. 2023 16h05 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
21 nov. 2023 16h05 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...